Erythropoietin gene therapy - Oxford BioMedica

Drug Profile

Erythropoietin gene therapy - Oxford BioMedica

Alternative Names: Repoxygen

Latest Information Update: 13 Aug 2003

Price : $50

At a glance

  • Originator Oxford BioMedica
  • Class Antianaemics; Gene therapies; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 13 Aug 2003 Discontinued - Preclinical for Anaemia in United Kingdom (Injection)
  • 28 Oct 2002 Final study results of a preclinical study have been added to the pharmacodynamics section
  • 24 Jun 2002 Preliminary preclinical study results have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top